Where AI meets biology — the breakthroughs changing diagnosis, treatment, and prevention. Daily coverage of AI drug discovery, digital therapeutics, FDA milestones, and the startups building the future of healthcare.
Blog / RSS8 sources · 50 posts
‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1 - MedCity News
medcitynews.com·Jul 15, 2026
Digital health startups raised $7.4 billion in the first half of 2026, an increase from $6.4 billion in the same period in 2025, with a notable concentration of funding in larger deals, particularly in mental health and weight management sectors. Investors are increasingly prioritizing founder expertise and unique competitive advantages over mere AI capabilities, reflecting a shift in market dynamics.
For a professional tracking healthtech and related fields, the key insight is that AI is no longer a unique selling point in digital health; instead, investors are prioritizing founder expertise, plat...
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer - MedCity News
medcitynews.com·Jul 15, 2026
Celcuity has received FDA approval for its new breast cancer treatment, Revtorpyk, which targets HR-positive, HER2-negative breast cancer without PIK3CA mutations, using a dual approach to inhibit key cancer pathways. The drug is expected to launch in late Q3 2023, with a potential market opportunity exceeding $10 billion, and plans for further studies in other cancer types are underway.
The FDA approval of Celcuity's Revtorpyk, a first-in-class drug targeting both PI3K and mTOR pathways in HR-positive, HER2-negative breast cancer, presents a significant market opportunity, estimated ...
Get this feed in your inbox
Free digest emails with the latest posts — no account needed.
J&J restructures pharma manufacturing footprint at cost of up to $750M
endpts.com·Jul 15, 2026
Johnson & Johnson plans to restructure its pharmaceutical manufacturing operations, which could cost up to $750 million, as part of an effort to optimize its supply chain and exit certain factories.
The content details Johnson & Johnson's plan to restructure its pharmaceutical manufacturing footprint, anticipating costs up to $750 million. For someone tracking investment signals in healthtech and...
I&I startup Attovia files to go public as biotech listings momentum builds
endpts.com·Jul 15, 2026
Attovia Therapeutics has filed for an initial public offering (IPO) as part of a growing trend of biotech companies seeking to go public. This marks the third biotech firm preparing for a listing in the upcoming weeks, reflecting increasing momentum in the sector.
Attovia Therapeutics, a biologics maker, has filed for an initial public offering, contributing to the growing momentum of biotech listings. This move could signal a favorable environment for biotech ...
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
techcrunch.com·Jul 15, 2026
OpenAI researcher Miles Wang is in discussions to launch a new AI drug discovery startup, potentially valued at $2 billion, with plans to raise around $200 million in funding. This venture aims to leverage AI for breakthroughs in life sciences, particularly in finding new uses for existing drugs, and is expected to attract other researchers from OpenAI.
Miles Wang, a former OpenAI researcher, is planning to launch an AI drug discovery startup with a significant $2 billion valuation and a potential $200 million funding round led by Lightspeed. This in...
Celcuity wins approval for breast cancer drug Revtorpyk
endpts.com·Jul 14, 2026
Celcuity has received FDA approval for its breast cancer drug Revtorpyk, which aims to enhance treatment options compared to existing therapies from Novartis and Roche.
Celcuity, a small public biotech company, achieved FDA approval for its breast cancer drug Revtorpyk, designed to improve upon treatments from major players like Novartis and Roche. This development h...
What's next for BINSA, the House bill restricting China deals
endpts.com·Jul 14, 2026
A bipartisan House bill aimed at restricting U.S. biotech companies from forming partnerships with Chinese firms has gained attention, reflecting growing concerns over competition and security in the biotech sector. The status and implications of this legislation are currently being discussed among lawmakers.
The content discusses a bipartisan bill in the U.S. aimed at restricting biotech deals with Chinese counterparts. For someone interested in healthtech, this highlights a significant regulatory develop...
Post-Hoc Live: What’s making biotech IPOs work again?
endpts.com·Jul 14, 2026
The upcoming Post-Hoc Live event will discuss the recent resurgence of biotech IPOs, featuring insights from CEOs of newly public companies and an IPO reporter, focusing on the factors contributing to this market revival and its sustainability. The discussion will take place on July 15 at 12 p.m. ET on YouTube.
The key insight for you, given your interest in biotech IPOs, is that the recent wave of successful biotech IPOs indicates a shift in the market dynamics, overcoming the false starts of previous years...
A health tech workaround is under fire
endpts.com·Jul 14, 2026
A recent settlement between California's attorney general and the bankrupt clinic company Carbon Health has raised concerns within the digital health industry regarding regulatory compliance and industry practices. This development serves as a warning for health tech companies to reassess their operations and adherence to legal standards.
The content does not provide specific insights or actionable takeaways relevant to your interests in healthtech, biotech, or related fields. The article mentions a legal settlement involving a digital...
Erasca's $550M offering; Summit sells an antibiotic
endpts.com·Jul 14, 2026
Erasca is targeting a $550 million public offering to support its KRAS drug development, while Summit has sold an antibiotic. Additional updates include news on subcutaneous Leqembi, WuXi AppTec, and Q32 Bio.
This content highlights Erasca's $550 million public offering aimed at funding the development of KRAS-targeted drugs. For someone tracking biotech and health startup investments, this presents a sign...
Genetic medicine startup Lyora launches with programs from Editas, Biogen
endpts.com·Jul 14, 2026
Lyora Therapeutics has launched to revive early-stage genetic eye disease programs that were previously stalled at Editas Medicine and Biogen, aiming to advance genetic medicine initiatives.
The content discusses the launch of Lyora Therapeutics, a genetic medicine startup aiming to advance stalled genetic eye disease programs from Editas Medicine and Biogen. For someone tracking biotech ...
AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy
endpts.com·Jul 14, 2026
AstraZeneca will acquire worldwide development and sales rights to Dizal's lung cancer drug Zegfrovy for $600 million upfront.
AstraZeneca's $600 million upfront acquisition of worldwide rights to Dizal's lung cancer drug, Zegfrovy, highlights a significant investment signal in the oncology sector, indicating a strategic focu...
In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic
endpts.com·Jul 14, 2026
Innovent Biologics is shifting its focus to smaller partnerships after collaborating with major pharmaceutical companies, as it seeks to advance Spero's future beyond its GSK-owned antibiotic.
The content doesn't provide specific insights directly relevant to your focus areas such as healthtech, digital health, or AI drug discovery. However, the mention of Innovent Biologics partnering with...
Former Akero team announces new I&I company, Avere, with China drug
endpts.com·Jul 14, 2026
The former executive team of Akero Therapeutics has launched a new company, Avere Therapeutics, focusing on inflammatory and immune (I&I) therapies, following Akero's $4.7 billion acquisition by Novo Nordisk. This development highlights the accelerating pace of biotech innovation in China.
The content highlights that the former executive team from Akero Therapeutics has launched a new company, Avere Therapeutics, focusing on immunology and inflammation, with a drug sourced from China. T...
Nearly 200 Organizations Back Bill to Expand Access to Clinical Trials - MedCity News
medcitynews.com·Jul 13, 2026
A coalition of 195 organizations has endorsed the Clinical Trial Modernization Act, which aims to enhance access to clinical trials for underrepresented groups by reducing financial barriers and providing support for non-medical expenses. The act would enable sponsors to offer financial assistance for travel, lodging, and childcare, and would also allow for remote participation, ultimately promoting greater diversity and accelerating medical innovation.
The Clinical Trial Modernization Act, supported by nearly 200 organizations, aims to increase access to clinical trials by addressing financial barriers for underrepresented groups, including providin...
Health tech funding rises to $7.4B in the first half of 2026
endpts.com·Jul 13, 2026
In the first half of 2026, digital health startups secured $7.4 billion in venture funding, marking a $1 billion increase compared to the same period in 2025.
Health tech startups have secured $7.4 billion in venture funding in the first half of 2026, marking a $1 billion increase from the same period in 2025. This growth in funding suggests a strong invest...
Reed Jobs would rather talk about curing cancer than his last name
techcrunch.com·Jul 12, 2026
Reed Jobs, son of Steve Jobs, prefers to focus on his biotech venture firm, Yosemite, which aims to develop innovative cancer treatments through a combination of philanthropy and investment. He emphasizes the rapid advancements in the biotech field, particularly due to AI, and discusses the firm's unique approach to creating new companies from early academic research.
Reed Jobs's venture firm, Yosemite, is leveraging AI to accelerate drug discovery and clinical trial design, especially within oncology. This approach is capitalizing on the unprecedented opportunitie...
Deals, deals, deals; Biohaven takes on Eli Lilly; and more
endpts.com·Jul 11, 2026
The article discusses recent developments in the biopharma industry, highlighting Biohaven's competition with Eli Lilly and the growing paranoia among American drugmakers due to rising competition from China. It also features insights into various industry partnerships and trends.
The content provided does not contain specific insights or actionable takeaways relevant to your interests in healthtech, biotech, digital health, or related areas. It primarily serves as a prompt to ...
Apnimed files for IPO as FDA reviews its sleep apnea drug
endpts.com·Jul 10, 2026
Apnimed has filed for an initial public offering (IPO) as the FDA reviews its sleep apnea drug, marking a significant step after years of consideration. The Cambridge-based biotech aims to advance its business following this pivotal milestone.
Apnimed's decision to file for an IPO as the FDA reviews its sleep apnea drug signals a strong investment opportunity in the biotech space, particularly for those interested in companies poised to add...
German lawmakers pass cost-saving bill that drugmakers say will drive them out
endpts.com·Jul 10, 2026
German lawmakers have passed a cost-saving healthcare bill that drug manufacturers argue could negatively impact their operations in the country, leading to significant criticism from the pharmaceutical industry.
The newly passed cost-saving bill by German lawmakers, aimed at reducing domestic healthcare spending, poses significant challenges for pharmaceutical companies operating in the region. This legislati...
IKS Health Beefs Up Its Tech Stack with $557M Acquisition of TruBridge - MedCity News
medcitynews.com·Jul 10, 2026
IKS Health has completed its $557 million acquisition of TruBridge, enhancing its healthcare software offerings by integrating TruBridge's EHR and revenue-cycle tools, particularly beneficial for small, rural hospitals. This acquisition is part of a broader trend in healthcare technology consolidation, aimed at creating comprehensive platforms that combine electronic records, billing, and AI tools to address the administrative challenges faced by rural healthcare providers.
The acquisition of TruBridge by IKS Health is a strategic move to expand IKS' reach among small, rural hospitals, which are increasingly outsourcing EHR and billing functions due to financial and staf...
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
endpts.com·Jul 9, 2026
Ipsen has successfully completed Phase 3 trials for its injectable neurotoxin Dysport, showing positive results for treating migraines, while Tarsus has acquired iRenix for $75 million upfront.
The most valuable insight for someone interested in healthtech and biotech is Ipsen's successful completion of Phase 3 trials for their injectable neurotoxin, Dysport, in treating both episodic and ch...
Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down
endpts.com·Jul 9, 2026
Eli Lilly has emerged as a dominant player in biotech acquisitions during the first half of 2026, leveraging its significant financial resources and success in obesity treatments to drive its growth strategy without indications of slowing down.
Eli Lilly's aggressive strategy in biotech acquisitions, leveraging its trillion-dollar valuation, positions it as a dominant player in the sector with no signs of slowing down. For investors and prof...
Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval - MedCity News
medcitynews.com·Jul 8, 2026
The FDA has approved Trutakna, a new treatment for primary immunoglobulin A nephropathy (IgAN) developed by Vera Therapeutics, marking the first specific therapy for this rare autoimmune kidney disease. This once-weekly injection targets two proteins involved in the disease, showing significant efficacy in reducing proteinuria, and is positioned to compete with existing therapies in a growing market for autoimmune treatments.
The recent FDA approval of Vera Therapeutics' Trutakna for primary immunoglobulin A nephropathy (IgAN) highlights a significant advancement in targeted therapies, as it is the first treatment specific...
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
endpts.com·Jul 8, 2026
Prime Medicine has resolved a dispute with Beam Therapeutics regarding an AATD candidate, allowing it to proceed to clinical trials.
Prime Medicine's victory in the dispute with Beam Therapeutics over an AATD candidate highlights the importance of strategic litigation and intellectual property management in the biotech sector, espe...
Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships
endpts.com·Jul 8, 2026
Sino Pharmaceutical has entered into separate drug development and sales partnerships with AstraZeneca and GSK, focusing on respiratory treatments.
This content highlights that Sino Biopharmaceutical has formed drug development and sales partnerships with AstraZeneca and GSK focusing on respiratory health. For someone tracking healthtech and biot...
Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader
endpts.com·Jul 7, 2026
Vertex Pharmaceuticals has made a significant move in the biopharma industry by acquiring endocrinology startup Crinetics for $10 billion, signaling its ambitions to elevate its status within the sector.
Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, an endocrinology startup, signifies a strategic move to elevate its status in the biopharma sector. This deal highlights Vertex's ambition...
Tampa General kicks off legal fight over Lilly's 340B restrictions
endpts.com·Jul 7, 2026
Tampa General Hospital has initiated a lawsuit against Eli Lilly over the company's decision to halt its 340B drug discounts, raising broader questions about the legality of pharmaceutical companies imposing conditions on drug pricing.
The legal battle between Tampa General Hospital and Eli Lilly over 340B discount restrictions underscores the growing tension between healthcare providers and pharmaceutical companies regarding drug p...
How digital health companies are planning to conquer CMS ACCESS
endpts.com·Jul 7, 2026
Digital health companies are strategizing to navigate a new Medicare experiment aimed at managing chronic diseases in seniors, which offers limited financial incentives compared to their potential earnings.
The article highlights a new Medicare experiment focusing on managing seniors' chronic diseases, which presents an opportunity for digital health companies. These companies should explore strategies t...
French gene therapy biotech gets €33M to follow Krystal's blueprint
endpts.com·Jul 7, 2026
Cyllene Therapeutics, a French-US biotech company, has secured €33 million in funding to advance its HSV-based gene therapy, aiming to replicate the success of Krystal Biotech.
The key takeaway for someone tracking healthtech and biotech is that Cyllene Therapeutics, a French-US gene therapy startup, has secured €33 million in funding to advance its work in HSV-based gene th...
Vertex makes $10B deal for commercial endocrinology biotech Crinetics
endpts.com·Jul 6, 2026
Vertex Pharmaceuticals has announced a $10 billion acquisition of Crinetics Pharmaceuticals, marking its largest acquisition to date and enhancing its commercial portfolio in endocrinology.
Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals, a commercial endocrinology biotech, marks the largest acquisition in Vertex's history, indicating a significant strategic ...
Scribe Therapeutics files for IPO in test of appetite for early-stage biotechs
endpts.com·Jul 2, 2026
Scribe Therapeutics has filed for an IPO on Nasdaq, marking a significant moment for the biotech company and testing market interest in early-stage biotechs.
Scribe Therapeutics' filing for a Nasdaq IPO highlights a critical moment for gauging investor appetite for early-stage biotech companies, particularly in the gene editing sector. This development is ...
IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport
endpts.com·Jul 2, 2026
Celea Therapeutics has secured $180 million in funding to pursue its development goals, aiming to follow the successful paths of its sister companies, Seaport Therapeutics and Karuna Therapeutics.
The content highlights that Celea Therapeutics has secured $180 million in funding with the goal of following the successful paths of PureTech's other ventures, such as Karuna and Seaport Therapeutics...
Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist
endpts.com·Jul 2, 2026
Michel Dethue has been appointed as the new CEO of Danish neuro biotech Muna Therapeutics, succeeding Rita Balice-Gordon, while Genentech continues to experience losses with another key scientist departing.
The content does not provide any specific insights or actionable takeaways directly relevant to your interests in healthtech, biotech, or related fields. It primarily highlights personnel changes at M...
BridgeBio adds $1B as it prepares three more drug launches
endpts.com·Jul 1, 2026
BridgeBio Pharma has secured approximately $1 billion through a preferred equity deal to strengthen its resources in anticipation of launching three new drugs.
BridgeBio Pharma's successful $1 billion preferred equity financing signals strong investor confidence and positions the company well for the imminent launch of three new drugs. If you're tracking inv...
Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data
endpts.com·Jul 1, 2026
Angitia Pharmaceuticals has terminated its Phase 3 trial for AGA111 in patients with degenerative disc disease, while Abivax aims to raise $800 million based on promising data for its colitis treatment.
The most valuable insight for you is Abivax's intent to raise $800 million based on promising data for colitis, signaling a significant investment opportunity in the biotech sector focused on inflamma...
A June flourish lifts biotech megaround tally in first half of 2026
endpts.com·Jul 1, 2026
In the first half of 2026, forty private biotech companies reported funding rounds of $100 million or more, indicating a rebound in biotech megarounds during this period.
The most valuable insight for you is that there has been a significant rebound in biotech megarounds in the first half of 2026, with 40 private biotech companies each raising $100 million or more. Thi...
Health AI caution crosses into confidence
endpts.com·Jun 30, 2026
The perception of AI in healthcare has shifted significantly over the past year, moving from caution to increased confidence among health tech professionals, according to a report by venture firm Venrock.
The article highlights a significant shift in the perception of AI in healthcare, moving from caution to confidence. This suggests a growing acceptance and potential for investment opportunities in AI...
The AI Drug Discovery Race Is Heating Up, Not In the Way You Think - MedCity News
medcitynews.com·Jun 30, 2026
Since 2019, $60 billion has been invested in AI for drug discovery, yet no AI-originated drugs have received FDA approval, mirroring traditional drug development timelines. The upcoming trials of advanced AI-designed drugs will reveal the effectiveness of different AI approaches, emphasizing the importance of the underlying training data in determining success.
The key takeaway for you is the importance of scrutinizing the underlying data in AI drug discovery. As AI-designed drugs approach critical mid- and late-stage trials, it's crucial to differentiate be...
House China panel probes Bristol Myers, Pfizer on use of trial sites
endpts.com·Jun 30, 2026
A congressional committee is investigating Bristol Myers Squibb and Pfizer regarding their use of clinical trial sites in China, raising concerns about the implications of conducting trials in that region.
The content does not provide a specific insight relevant to your interests in healthtech, biotech, or digital health sectors. It mainly focuses on a congressional inquiry into Bristol Myers Squibb and...
Zymeworks CEO on why the Theravance deal is value for money
endpts.com·Jun 29, 2026
Zymeworks CEO Kenneth Galbraith defended the nearly $1 billion acquisition of Theravance, arguing that the deal represents good value for money despite Theravance's financial struggles.
The content does not provide any specific insight relevant to your interests in healthtech, biotech, digital health, or related areas, as it focuses on a high-level business deal involving Zymeworks a...
Evommune's lead drug fails in chronic hives, stock sinks
endpts.com·Jun 29, 2026
Evommune's lead drug for treating chronic hives has failed in its first major trial, leading to a more than 30% drop in the company's stock price following the announcement.
The most valuable insight for a professional in healthtech and biotech from this content is the significant impact of clinical trial outcomes on biotech stock performance. Evommune's lead drug failure...
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
endpts.com·Jun 29, 2026
Talawar Therapeutics is set to go public on the Nasdaq through a SPAC deal, while AstraZeneca has achieved a Phase 3 win in treating a children's bone disease.
The most valuable insight for you is the trend of biotech companies utilizing SPACs (Special Purpose Acquisition Companies) to accelerate their path to Nasdaq listings, as demonstrated by Talawar Ther...
Zymeworks to acquire troubled biotech Theravance in $929M deal
endpts.com·Jun 29, 2026
Zymeworks has announced its acquisition of troubled biotech company Theravance for $929 million, aiming to address the latter's ongoing challenges.
The acquisition of Theravance Biopharma by Zymeworks for $929 million highlights a strategic move in the biotech sector, signaling potential opportunities for restructuring and value creation in troub...
Lycia raises $75M for food allergy and Graves’ disease
endpts.com·Jun 26, 2026
Lycia Therapeutics has raised $75 million to advance its protein degradation platform, which targets food allergies and Graves' disease, co-founded by Nobel laureate Carolyn Bertozzi.
Lycia Therapeutics has successfully raised $75 million to advance its protein degradation platform, which could present significant opportunities in developing treatments for food allergies and Graves...
How Epicrispr is using 'digital twins' to study a muscle disease therapy
endpts.com·Jun 26, 2026
Epicrispr Biotechnologies is utilizing 'digital twins' technology to advance its research on an epigenetic editing therapy for a genetic muscle disease, with preliminary data recently shared.
The content highlights Epicrispr Biotechnologies' innovative use of 'digital twins' to study an epigenetic editing therapy for a genetic muscle disease. For someone in your field, this underscores th...
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
endpts.com·Jun 26, 2026
Biogen has decided to pause or cancel most of the research programs acquired from its $5.6 billion purchase of Apellis Pharmaceuticals, resulting in significant layoffs.
Biogen's decision to pause or cancel the majority of research programs following its $5.6 billion acquisition of Apellis Pharmaceuticals underscores a strategic shift towards prioritizing high-potenti...
STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better
statnews.com·Jun 25, 2026
At the BIO 2026 conference in San Diego, biotech executives discussed challenges posed by China's growing influence in drug development, the impact of U.S. political dynamics on drug pricing, and strategies to leverage artificial intelligence for competitive advantage in the industry.
The most valuable insight from the BIO 2026 conference for a professional in healthtech and biotech is the industry's focus on leveraging artificial intelligence for competitive advantage amidst risin...
STAT+: The China debate gets louder in Washington
statnews.com·Jun 25, 2026
The article discusses recent developments in biotech, including Eli Lilly's investment in AI-designed hair loss treatments, a significant increase in U.S. health care spending driven by GLP-1 drugs, and the growing debate in Washington regarding China's expanding role in the biopharmaceutical sector.
The most valuable insight from the content is the focus on Eli Lilly's investment in the AI startup Absci for developing an experimental AI-designed hair loss drug. This signals a growing trend of lev...
STAT+: Pharmalittle: We’re reading about weight loss drug spending, launch prices for medicines, and much more
statnews.com·Jun 25, 2026
A recent report highlights a significant increase in U.S. health care spending, particularly driven by weight loss drugs, which contributed to an overall rise of 7.3% in 2025, amounting to $5.7 trillion. Additionally, new advancements in treatments for aggressive breast cancer have emerged, with FDA approvals for innovative drugs like Gilead's Trodelvy and AstraZeneca's Datroway.
The significant takeaway for someone in your field is the sharp increase in healthcare spending driven by the surge in prescription drug costs, notably weight loss drugs. This trend indicates potentia...
Build your own newsroom
Add your own sources, define your topics, and get personalized digests delivered to your inbox.